Capsulotomy triggers prostaglandin release in FLACS

Article

Anterior capsulotomy triggers an increase of prostaglandins in the aqueous humour immediately after FLACS, according to researchers from Ruhr University Eye Hospital, Bochum, Germany.

Anterior capsulotomy is the main trigger for an increase of prostaglandins in the aqueous humour that occurs immediately after femtosecond laser-assisted cataract surgery (FLACS), according to researchers from the Institute for Vision Science and the Experimental Eye Research Institute, Ruhr University Eye Hospital, Bochum, Germany.

Reporting in the Journal of Refractive Surgery, the researchers collected the aqueous humour from 67 patients twice: once after the pretreatment for FLACS (only capsulotomy, only fragmentation, or both) and again at the beginning of routine cataract surgery. They then used an enzyme-linked immunoassay to measure total prostaglandin levels in all four groups.

Significantly higher levels of aqueous humour prostaglandins were detected immediately after the procedure in patients who underwent both capsulotomy and fragmentation (330.6 ± 110.6 pg/mL) or only laser capsulotomy 362.4 ± 117.5 pg/mL), compared to the control group (52.5 ± 8.1 pg/mL).

Patients who underwent only FLACS fragmentation did not demonstrate a prostaglandin increase (186.8 ± 114.0 pg/mL).

The researcher concluded that it may be possible to reduce laser-induced miosis by optimizing the laser’s energy settings and using nonsteroidal anti-inflammatory drugs.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.